Ionis Pharmaceuticals, Inc. (IONS) Presents at TD Cowen 46th Annual Health Care Conference Transcript

TD Cowen 46th Annual Health Care Conference March 2, 2026 10:30 AM ESTCompany ParticipantsBrett Monia - Founder, ...

Ionis Pharmaceuticals, Inc. (IONS) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript

Oppenheimer 36th Annual Healthcare Life Sciences Conference February 26, 2026 12:00 PM ESTCompany ParticipantsBrett ...

Needham Lifts PT on Ionis Pharmaceuticals (IONS) to $103 From $90

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the best strong buy healthcare stocks to invest in. Ionis Pharmaceuticals ...

Ionis Priority Review And DAWNZERA Data Reframe Rare Disease Growth Story

Ionis Pharmaceuticals received FDA Priority Review for its supplemental New Drug Application for olezarsen, targeting severe hypertriglyceridemia and reduction of acute pancreatitis risk. The company ...
BioSpace

Ionis Paves Its Own Path as Initial Tryngolza Launch Defies Expectations

Long an R&D company that partnered off assets, RNAi biotech Ionis Pharmaceuticals shifted in 2025 to bring two medicines to market alone. Analysts are already impressed—and there’s more to come in ...
PharmiWeb

Ionis reports fourth quarter and full year 2025 financial results and highlights progress on key programs

TRYNGOLZA® generated $108 million in net product sales in 2025, the first year of launch –- Olezarsen sHTG launch preparations on track, sNDA submitted -- Exceeded 2025 financial guidance, 2026 ...
Benzinga.com

Ionis Pharmaceuticals Partners With Japan-Based Ono Pharmaceutical For Rare Blood Disease Drug In Over $800 Million Deal

On Tuesday, Ionis Pharmaceuticals Inc (NASDAQ:IONS) and Ono Pharmaceutical Co., Ltd entered into a license agreement in which Ono obtains exclusive global rights for the development and ...

Ionis Pharmaceuticals: Q4 Earnings Snapshot

CARLSBAD, Calif. (AP) — CARLSBAD, Calif. (AP) — Ionis Pharmaceuticals Inc. (IONS) on Wednesday reported a loss of $229 million in its fourth quarter. On a per-share basis, the Carlsbad, ...
AOL

Ionis Pharma's Investigational Drug Shows Promise For Triglyceride And Pancreatitis Reduction

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) on Tuesday released topline results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen for severe hypertriglyceridemia (sHTG). sHTG is a condition ...
Business Wire

Ionis and Ono announce global license agreement for sapablursen in polycythemia vera

CARLSBAD, Calif. & OSAKA, Japan--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Ono Pharmaceutical Co., Ltd (Ono), today announced that the two companies have entered into a license ...
Benzinga.com

Tale Of Two Ionis-Partnered Neurology-Focused Early Stage Assets-Biogen Discontinues One, Decides Not To Exercise Licensing Option For Another

Thursday, Ionis Pharmaceuticals Inc (NASDAQ:IONS) and Biogen Inc (NASDAQ:BIIB) decided to terminate the development of BIIB105 (ION541), an investigational antisense oligonucleotide (ASO) for ...